ライフサイエンスコーパス: nasal congestion

1 il counts and lung function and increases in nasal congestion.

2 st agents are not very effective in treating nasal congestion.

3 th 35.3% in subjects without both asthma and nasal congestion.

4 ns of five patients with symptoms of chronic nasal congestion.

5 sophageal reflux disease, and 54 percent had nasal congestion.

6 73, five studies, I(2)=10%, tau(2)<0.001) or nasal congestion (0.42, 0.18 to 0.97, three studies, I(2

7 male sex (-0.26; 95% CI, -0.54 to 0.02), and nasal congestion (-0.28; 95% CI, -0.66 to 0.09) were ass

8 with etripamil were nasal discomfort (23%), nasal congestion (13%), and rhinorrhea (9%).

9 The most common adverse events were nasal congestion (16% of patients) and myalgia (14%).

10 most often within 5 days of inoculation were nasal congestion (36%), headache (30%), and sore throat

11 oarseness (2.0 days and 3.0 days; P = 0.02), nasal congestion (4.0 days and 6.0 days; P = 0.002), nas

12 ring exacerbations: 73% had lacrimation, 51% nasal congestion, 46% conjunctival injection and 40% pto

13 , sore throat (59.95%), hoarseness (57.90%), nasal congestion (53.39%).

14 In the subgroup reporting both asthma and nasal congestion, 55.8% had insomnia symptoms compared w

15 most common sinonasal symptoms reported were nasal congestion (62.8%; 95% Cl, 60.2%-65.4%) and change

16 RSV was more commonly associated with nasal congestion (68% vs. 55%; P=.03), wheezing by histo

17 symptom data, the most common symptoms were nasal congestion (72%), cough (64%), headache (59%), and

18 lergic rhinitis were rhinorrhea (90.38%) and nasal congestion (94.23%).

19 ress (82%), chronic cough (99%), and chronic nasal congestion (97%).

20 frequency of abdominal pain, diarrhoea, and nasal congestion after all three vaccinations was signif

21 nonallergic rhinitis present primarily with nasal congestion and postnasal drainage frequently assoc

22 As expected, nasal congestion and rhinorrhea were most common, but in

23 in the size of nasal polyps, the severity of nasal congestion and sinonasal symptoms, and the use of

24 Some also present with nasal congestion and subjective olfactory impairment.

25 al cytokine levels, nasal secretion weights, nasal congestion and symptom scores were determined.

26 respiratory distress in >80% of cases, daily nasal congestion and wet cough starting soon after birth

27 9 years (vs 50-64 years), symptoms of cough, nasal congestion and wheezing, and longer interval from

28 y group included peripheral edema, headache, nasal congestion, and anemia.

29 de overweight and obesity, alcohol, smoking, nasal congestion, and estrogen depletion in menopause.

30 exposure to seasonal pollen causes itching, nasal congestion, and repeated sneezing, with profound e

31 Initial symptoms included fever, cough, nasal congestion, and sore throat.

32 the reslizumab groups were headache, cough, nasal congestion, and upper respiratory tract infection.

33 ty breathing, fast breathing, runny nose, or nasal congestion; and current runny nose, nasal congesti

34 had a beneficial effect on airway symptoms (nasal congestion, anterior rhinorrhea, loss of sense of

35 Rhinitis medicamentosa with nasal congestion appears readily reversible with suitabl

36 Uncontrolled asthma and nasal congestion are important, treatable risk factors f

37 ute for vaccinating infants, who may develop nasal congestion as a result of intranasal vaccination.I

38 Notably, mild oliguria, moderate nasal congestion, bitter taste , throat discomfort, alon

39 asal spray (alpha adrenergic agonist) causes nasal congestion by rhinitis medicamentosa.

40 onist JNJ-39220675 relieved allergen-induced nasal congestion by using standard nasal symptom scoring

41 % difference; P = 0.02) but not with reduced nasal congestion compared with the control spray.

42 or nasal congestion; and current runny nose, nasal congestion, fever, chest indrawing, or cyanosis.

43 Nasal symptoms (mainly nasal congestion) followed by breathing disorders, gener

44 ms that lower their quality of life, such as nasal congestion, headache, sleep disturbance, daytime s

45 creased the likelihood of reporting frequent nasal congestion in the past 12 months.

46 ptor antagonist, JNJ-39220675, in preventing nasal congestion induced by exposing participants with r

47 In patients with allergic rhinitis, nasal congestion is a risk factor for apnea and snoring.

48 at least 1 point in Nasal Polyp Score (NPS), nasal congestion (NC) score, and loss of smell (LoS) sco

49 e geometries between two different levels of nasal congestion observed at distinct time points during

50 Coprimary end points were change in nasal congestion/obstruction at 4 weeks and summed bilat

51 Compared with all non-RSV-infected subjects, nasal congestion (odds ratio [OR], 2.0 [95% confidence i

52 1 had medium symptoms (13.6%), 1 had medium nasal congestion only (20.4%), and 1 had low symptoms (4

53 -1.51; p<0.0001) in SINUS-52; difference in nasal congestion or obstruction score was -0.89 (-1.07 t

54 eline to week 24 in nasal polyp score (NPS), nasal congestion or obstruction, and sinus Lund-Mackay C

55 Current smoking, stroke, epilepsy, and nasal congestion or upper respiratory tract infection we

56 and less likely among participants reporting nasal congestion (OR 0.1, 95% CI: .03-.8).

57 Nasal congestion (OR 1.50), obesity (OR 1.54) and smokin

58 conjunctival injection, 58% rhinorrhoea, 54% nasal congestion, ptosis and facial flushing.

59 rs but can include red itchy eyes, sneezing, nasal congestion, rhinorrhea, coughing, bronchoconstrict

60 rhinitis typically presents with symptoms of nasal congestion, rhinorrhea, postnasal drainage, sneezi

61 such as conjunctival injection, lacrimation, nasal congestion, rhinorrhoea, ptosis or eyelid oedema.

62 Significant improvement was observed in the nasal congestion score (P = 0.01) and sense of smell sco

63 < .0001) and -0.90 versus -0.31 (P = .0140); Nasal Congestion Score, -0.89 versus -0.35 (P = .0004) a

64 nt in nasal polyp score (primary end point), nasal congestion score, Sinonasal Outcome Test 22 score,

65 ne to week 24 in Nasal Polyp Score (NPS) and Nasal Congestion Score.

66 interval [CI], -2.39 to -1.74) and the mean nasal-congestion score (-1.03; 95% CI, -1.20 to -0.86) (

67 ores indicate greater severity) and the mean nasal-congestion score (range, 0 to 3; higher scores ind

68 , nasal airflow, nasal secretion weight, and nasal congestion scores.

69 rgic rhinitis is associated with symptoms of nasal congestion, sneezing, and itching of the eyes, nos

70 tom scores for sore throat, nasal discharge, nasal congestion, sneezing, cough, scratchy throat, hoar

71 and colds (no fever, and >/=2 of runny nose, nasal congestion, sneezing, sore throat, cough, swollen

72 st one of the following: cough, rhinorrhoea, nasal congestion, sore throat, difficulty breathing, and

73 of the following: myalgia, cough, runny nose/nasal congestion, sore throat, or difficulty breathing.

74 smell loss without significant rhinorrhea or nasal congestion suggests that SARS-CoV-2 targets the ch

75 matic treatments for pain, fever, cough, and nasal congestion to use as needed.

76 nd placebo recipients except that runny nose/nasal congestion was significantly more common in LAIV r

77 All the assessments except nasal congestion were slightly better in Cedarcure((R))

78 to Me-PFOSA-AcOH may be related to frequent nasal congestion, while other PFAS may have complex, mix